This page in Swedish

Susanne Bejerot

Susanne Bejerot Position: Professor Emerita School/office: School of Medical Sciences

Email: c3VzYW5uZS5iZWplcm90O29ydS5zZQ==

Phone: +46 701 655102

Room: USÖ

Susanne Bejerot
Research subject Research environments

About Susanne Bejerot

Research area: Immunopsychiatry

Susanne Bejerot is Professor Emerita of Psychiatry, Senior Consultant Psychiatrist in Region Örebro County, and a licensed cognitive psychotherapist. Her research is primarily clinical and has over the years focused on symptom assessment and treatment of individuals with obsessive–compulsive disorder (OCD), Pediatric Acute-onset Neuropsychiatric Syndrome (PANS and PANDAS), ADHD, autism spectrum disorder (with or without intellectual disability), and psychotic disorders. She has also conducted research in psychiatric comorbidity, vitamin D deficiency, oral health, gender identity aspects, joint hypermobility in relation to psychiatric symptoms, bullying and its association with gross motor function, psychiatric rating scales, and diagnostic methods.

Professor Bejerot has worked for many years on the development and refinement of psychiatric assessment instruments to support diagnostic evaluation. Instruments she has developed include the BOCS, RAADS-14 Screen, and Five to Fifteen-Brief. She has also developed the PsychoNeuroInflammatory related Signs and Symptoms Inventory (PNISSI), intended to facilitate clinical assessment of complex psychiatric conditions such as PANS.

In 2022, she completed a study in which severely affected psychiatric patients with either schizophrenia or obsessive–compulsive disorder were treated with the immunomodulatory drug Rituximab, a medication commonly used in severe rheumatoid arthritis and multiple sclerosis. Between 2023 and 2026, the RCT-RITS study was conducted, in which 123 patients with psychotic disorders were treated with rituximab or placebo. Results are expected to be published in 2027. The study was funded by the Swedish Research Council, the Torsten Söderström Foundation, and the Swedish Brain Foundation.

A three-year follow-up treatment study (RITS-LONG) is currently being planned for participants from the RCT-Rits trial, offering open-label treatment with rituximab for up to three years. This study will be led by Associate Professor Axel Nordenskjöld.

Susanne Bejerot’s professional goal has consistently been to conduct clinically grounded research for underserved patient groups with lifelong functional impairments and substantial care needs. Her ambition is to collaborate with other researchers to identify biological markers in blood or other body fluids and to develop novel treatment approaches—particularly immunological therapies—for severe mental illness.

Academic positions (CV)

  • 2024– Professor Emerita, School of Medical Sciences, Örebro University
  • 2015–2024 Professor, School of Medical Sciences, Örebro University
  • 2010 Associate Professor (Docent), Department of Clinical Neuroscience, Karolinska Institutet
  • 2000 PhD in Medicine, Uppsala University
  • 1997 Licensed Cognitive Behavioural Psychotherapist
  • 1995 Specialist in General Psychiatry
  • 1989 Medical License, Karolinska Institutet


Doctoral thesis

Obsessive-compulsive disorders – personality traits and disorders, autistic traits and biochemical findings.
Uppsala University, 2000.
Supervisor: Professor Lars von Knorring.


Principal supervisor

  • Ulrika Hylén, School of Medical Sciences, Örebro University. Immunopsychiatry from a transdiagnostic perspective – the immunometabolic interplay. PhD 2022. Co-supervisors: Eva Särndahl, Daniel Eklund.
  • Martin Glans, School of Medical Sciences, Örebro University. Joint hypermobility and its association with ADHD, autism, and motor function. PhD 2022. Co-supervisor: Marie Elwin.
  • Eva Hesselmark, Department of Clinical Neuroscience, Karolinska Institutet. Pediatric Autoimmune Neuropsychiatric Syndrome – symptoms, biomarkers, assessment and treatment. PhD 2019. Co-supervisor: Gustav Nilsonne
  • Jonna Eriksson, MD, Department of Clinical Neuroscience, Karolinska Institutet. Gender aspects and biological parameters in adults with autism spectrum disorder. PhD 2016. Co-supervisor: Elias Eriksson
  • Irina Manouilenko, MD, Department of Clinical Neuroscience, Karolinska Institutet. Autism spectrum disorder in adults – biological dimensions. PhD 2013. Co-supervisor: Marco Pagani


Co-supervisor

  • Simon Bylund, School of Medical Sciences, Örebro University. Rituximab as treatment for psychotic disorders – from clinical phenotype to biochemical markers. Principal supervisor: Sverre Wikström; Co-supervisor: Daniel Eklund (ongoing)
  • Karin Jacobson, School of Medical Sciences, Örebro University. Psychotic disorders – changes following treatment from a patient and family perspective. Principal supervisor: Sanna Aila Gustafsson, Co-supervisor: Lise Bergman Nordgren
  • Britta Westerberg, School of Medical Sciences, Örebro University. I-ALMA – Internet-based treatment for adults with autism spectrum disorder and normal intelligence. PhD 2025. Principal supervisor: Fredrik Holländare.
  • Katarzyna Popiolek, School of Medical Sciences, Örebro University. Outcomes of electroconvulsive therapy in bipolar disorder. PhD 2024. Principal supervisor: Axel Nordenskjöld
  • Eleonore Rydén, MD, Department of Clinical Neuroscience, Karolinska Institutet. Attention Deficit Hyperactivity Disorder in Bipolar Disorder. PhD 2010. Principal supervisor: Mikael Landén


Postdoctoral supervision

  • My Blomqvist, DDS, Department of Dental Medicine, Karolinska Institutet. Evaluation of oral health in adults with ADHD or autism spectrum disorder. 2008–2010. Principal supervisor: Göran Dahllöf

Publications

Articles in journals |  Articles, reviews/surveys |  Chapters in books |  Conference papers |  Manuscripts | 

Articles in journals

Articles, reviews/surveys

Chapters in books

Conference papers

Manuscripts